Skip to main content
. Author manuscript; available in PMC: 2024 May 16.
Published in final edited form as: Immunity. 2023 Feb 2;56(2):353–368.e6. doi: 10.1016/j.immuni.2023.01.007

Figure 4. GF mice transplanted with healthy microbiome showed reduced GVHD.

Figure 4.

(A to C) Germ free B6 (GF) mice were gavaged intestinal content from Syn and Allo BMT recipient mice. (A) Body weight change is shown (GF: N=2, GF with Syn B6 stool: N=4, GF with Allo B6 stool: N=5). Stool from GF with Syn or Allo B6 stool 4weeks after stool gavage analyzed by 16S rRNA gene sequencing. PCoA (B) and microbiome composition (C) are shown (GF with Syn B6 stool: N=7, GF with Allo B6 stool: N=10). (D to F) SPF B6 and GF B6 mice received BMT from B6 or BALB/c donor. Survival rate (D), body weight change (E), and clinical GVHD score (F) are shown (GF Syngeneic: N=2, GF Allogeneic: N=18, SPF Syngeneic: N=2, SPF Allogeneic: N=17). (G to J) GF B6 mice received BMT from B6 or BALB/c donor. Then GF mice were gavaged intestinal content from SPF Syn and SPF Allo BMT recipient mice (G). Survival rate (H) and clinical GVHD score 6 weeks after BMT (I) are shown (Allo GF with Syn B6 stool N=6, Allo GF with Allo B6 stool N=4). (J) Ileum and colonic histopathological score at day7 after BMT are shown (n=4). Two-tailed unpaired t-test (A, I, J), log-rank test (D, H), and two-tailed Mann-Whitney test (F) was used to determine (mean ± s.e.m.). *P < 0.05, ***P<0.001, ****P<0.0001. See also Figure S4.